TY - JOUR T1 - Highlights from this issue JF - Frontline Gastroenterology JO - Frontline Gastroenterol SP - 1 LP - 2 DO - 10.1136/flgastro-2021-102066 VL - 13 IS - 1 AU - R Mark Beattie Y1 - 2022/01/01 UR - http://fg.bmj.com/content/13/1/1.abstract N2 - Neuroendocrine tumours are more common than we might think (annual incidence 7-8/100,000). The the most common primary sites are the gut and pancreas. In this issue Khan and colleagues provide a comprehensive overview. There are multiple tumour types. Diagnostic delay is common as symptoms can be similar to, for example, irritable bowel syndrome. The authors helpfully discuss the clinical features and investigation when NETS are suspected including biochemistry (not helpful for screening), CT/MRI/Nuclear Medicine and Endoscopy. Diagnosis is by histology. Treatment requires a comprehensive work up and multidisciplinary team discussion. Tumour resection is usually advised for localised NETS. Long-acting somatostatin analogues are the treatment of choice for unresectable low-grade NETS. There are multiple other treatment options for more extensive disease. Outcome is generally good influenced by tumour site, size and spread at diagnosis (appendiceal NETS have the best prognosis). Gastroenterologists have a a key role to play in the whole pathway including in particular the longer-term control of gut symptoms. This is a very comprehensive update. Read and enjoy, listen to the accompanying podcast. (See page 50) The demand for bowel cancer screening is expected to continue to … ER -